Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 4/2000

01.07.2000 | Review Article

Safety of Routine Childhood Vaccinations

An Epidemiological Review

verfasst von: Dr Robert T. Chen, Gina Mootrey, Frank DeStefano

Erschienen in: Pediatric Drugs | Ausgabe 4/2000

Einloggen, um Zugang zu erhalten

Abstract

Immunisations have been one of the most cost-effective public health interventions in human history. Despite remarkable progress, several challenges face immunisation programs worldwide. Paradoxically, despite vaccines’ clear effectiveness in reducing risks of diseases that were previously widely prevalent and caused substantial morbidity and mortality, current vaccination policies have become increasingly controversial due to concerns about vaccine safety.
Vaccines, like other pharmaceutical products, are not entirely risk-free. While most known adverse effects are minor and self-limited, some vaccines have been associated with very rare but serious adverse effects. Because such rare effects are often not evident until vaccines come into widespread use, ongoing surveillance programs to monitor vaccine safety are needed. Such monitoring will be essential if the public is to accept the increasing number of new vaccines made possible by biotechnology. The interpretation of data from vaccine safety research is complex and is associated with some uncertainty. Effectively communicating this uncertainty and continuing to improve understanding of rare risks and risk factors are essential for “mature” immunisation programs to maintain public confidence in immunisations.
Literatur
1.
World Bank. World development report 1993: investing in health. New York (NY): Oxford University Press, 1993
2.
Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication. Geneva: World Health Organization, 1988
3.
Centers for Disease Control and Prevention. Progress toward global poliomyelitis eradication 1997–1998. MMWR Morb Mortal Wkly Rep 1999 May 28; 48(20): 416–21
4.
Department of vaccines and other biologicals: annual report 1998. Geneva: World Health Organization, 1999
5.
Chen RT, Rastogi SC, Mullen JR, et al. The vaccine adverse event reporting system (VAERS). Vaccine 1994; 12: 542–50PubMedCrossRef
6.
Kemp T, Pearce N, Fitzharris P, et al. Is infant immunization a risk factor for childhood asthma or allergy? Epidemiology 1997; 8: 678–80PubMed
7.
Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and regressive developmental disorder in children. Lancet 1998; 351: 637–41PubMedCrossRef
8.
Classen DC, Classen JB. The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus. Infect Dis Clin Pract 1997; 6: 449–54CrossRef
9.
Gout O, Lyon-Caen O. Sclerose en plaques et vaccination contre le virus de l’hepatite B. Rev Neurol Paris 1998; 154: 205–7PubMed
10.
Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Rep 1997; 112: 10–20PubMed
11.
Chen R. Safety of vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia (PA): WB Saunders, 1999: 1144–63
12.
Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of the anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351: 356–61PubMedCrossRef
13.
Fourrier A, Touzé E, Alpévovitch A, et al. Association between hepatatis B vaccine and multiple sclerosis: a case-control study. Pharmacoepidemiol Drug Saf 1999; 8 (Suppl. 2): S140–1
14.
Communicable Disease Surveillance Centre. Sentinel surveillance shows small decline in MMR coverage. Commun Dis Rep CDR Wkly 1998; 8: 317–20
15.
Howson CP, Howe CJ, Fineberg HV, editors. Adverse effects of pertussis and rubella vaccines. Washington, DC: National Academy Press, 1991
16.
Brown F, Greco D, Mastrantonio P, et al. Pertussis vaccine trials. Dev Biol Stand 1997; 89: 1–407
17.
Osvath P, Csorba S, Endre L, et al. IgE levels of infants with complications after pertussis vaccination. Allergol Immunopathol (Madr) 1979; 7: 111–4
18.
Pollock TM, Morris J. A 7 year survey of disorders attributed to vaccination in North West Thames region. Lancet 1983; 1: 753–7PubMedCrossRef
19.
Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1996 Sep 6; 45(RR-12): 1–35
20.
Centers for Disease Control and Prevention. Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998; 47(RR-8): 1–58
21.
Farrington CP, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345: 567–9PubMedCrossRef
22.
Nieminen U, Peltola H, Syrjala MT, et al. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination: a report on 23 patients. Acta Paediatr 1993; 82: 267–70PubMedCrossRef
23.
Bottiger M, Christenson B, Romanus V, et al. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 1987; 295: 1264–7CrossRef
24.
Prevots DR, Sutter RW, Strebel PM, et al. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991: implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med 1994; 148: 479–85PubMedCrossRef
25.
Freestone DS, Prydie J, Smith SG, et al. Vaccination of adults with Wistar RA 27/3 rubella vaccine. J Hygiene 1971; 69: 471–7CrossRef
26.
Polk BF, Modlin JF, White JA, et al. A controlled comparison of joint reactions among women receiving one of two rubella vaccines. Am J Epidemiol 1982; 115: 19–25PubMed
27.
Chen RT, Glasser J, Rhodes P, et al. The vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 1997; 99: 765–73PubMedCrossRef
28.
Chen RT. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strom BL, editor. Pharmacoepidemiology. Chichester, Sussex: John Wiley & Sons, 2000. In press
29.
Cherry JD. Pertussis and the vaccine controversy. In: Root RK, Warren KS, Griffiss JM, et al., editors. Contemporary issues in infectious diseases. New York (NY): Churchill Livingstone, 1989: 47–63
30.
Goodman M, Lamm SH, Bellman MH. Temporal relationship modeling: DTP or DT immunizations and infantile spasms. Vaccine 1998; 16: 225–31PubMedCrossRef
31.
Stratton KR, Howe CJ, Johnston Jr RB, editors. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington, DC: National Academy Press, 1994
32.
Stratton KR, Howe CJ, Johnston RB, editors. DPT vaccine and chronic nervous system dysfunction: a new analysis. Institute of Medicine. Washington, DC: National Academy Press, 1994
33.
Tuttle J, Chen RT, Rantala H, et al. The risk of Guillain-Barré syndrome after tetanus-toxoid containing vaccines in adults and children. Am J Public Health 1997; 87: 2045–8PubMedCrossRef
34.
Miller DL, Ross EM, Alderslade R, et al. Pertussis immunisation and serious acute neurological illness in children. BMJ 1981 May 16; 282: 1595–9PubMedCrossRef
35.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. Am J Epidemiol 1979; 110: 105–23PubMed
36.
Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46 (No. RR-3): 1–25
37.
Rosenthal S, Chen R, Hadler SC. The safety of acellular pertussis vaccine versus whole cell pertussis vaccine: a post-marketing assessment. Arch Pediatr Adolesc Med 1996; 150: 457–60PubMedCrossRef
38.
Pichichero ME. Acellular pertussis vaccines: towards an improved safety profile. Drug Saf 1996; 15: 311–24PubMedCrossRef
39.
Roberts JD, Roos LL, Poffenroth LA, et al. Surveillance of vaccine-related adverse events in the first year of life: a Manitoba cohort study. J Clin Epidemiol 1996; 49: 51–8PubMedCrossRef
40.
Davis RL, Barlow W, Thompson RS, et al. Seizures following DPT or MMR vaccination among neurologically impaired or at-risk children: results from the vaccine safety datalink study. 32nd National Immunization Conference; 1998 July 21–24; Atlanta, 152
41.
Davis RL, Barlow W, Thompson RS, et al. Seizures following DPT or MMR vaccination among a cohort of neurologically impaired or at-risk children: results from the vaccine safety datalink study [abstract no. 514]. Pediatric Research 1998; 43(4): 90A
42.
Bellman MH, Ross EM, Miller DL. Infantile spasms and pertussis immunization. Lancet 1983: I: 1031–4CrossRef
43.
Shields WD, Nielsen C, Buch D, et al. Relationship of pertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study. J Pediatr 1988; 113: 801–5PubMedCrossRef
44.
Braun MM, Terracciano G, Salive ME, et al. Report of a US public health service workshop on hypotonic-hyporesponsive episode (HHE) after pertussis immunization. Pediatrics 1998; 102: E52PubMedCrossRef
45.
Vermeer-de Bondt PE, Labadie J, Rumke HC. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study. BMJ 1998; 316: 902–3PubMedCrossRef
46.
Miller D, Madge N, Diamond J, et al. Pertussis immunisation and serious acute neurological illnesses in children. BMJ 1993; 307: 1171–6PubMedCrossRef
47.
Walker AM, Jick H, Perera DR, et al. Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health 1987; 77: 945–51PubMedCrossRef
48.
Jonville-Bera AP, Autret E, Laugier J. Sudden infant death syndrome and diphtheria-tetanus-pertussis-poliomyelitis vaccination status. Fundam Clin Pharmacol 1995; 9: 263–70PubMedCrossRef
49.
Hoffman HS, Hunter JC, Damus K, et al. Diphtheria-tetanus-pertussis immunization and sudden infant death: results of the national institute of child health and human development cooperative epidemiological study of sudden infant death syndrome risk factors. Pediatrics 1987; 79: 598–611PubMed
50.
Griffin MR, Ray WA, Livengood JR, et al. Risk of sudden infant death syndrome (SIDS) after immunization with the diphtheria-tetanus-pertussis vaccine. N Engl J Med 1988; 319: 618–23PubMedCrossRef
51.
Bouvier-Colle MH, Flahaut A, Messiah A, et al. Sudden infant death and immunization: an extensive epidemiological approach to the problem in France — winter 1986. Int J Epidemiol 1989; 18: 121–6PubMedCrossRef
52.
Mitchell EA, Stewart AW, Clements M. Immunisation and the sudden infant death syndrome: New Zealand Cot Death Study Group. Arch Dis Child 1995 Dec; 73(6): 498–501PubMedCrossRef
53.
Rantala H, Uhari M, Tuokko H, et al. Poliovaccine virus in the cerebrospinal fluid after oral polio vaccination. J Infect 1989; 19: 173–6PubMedCrossRef
54.
Andronikou S, Siamopoulou-Mavridou A, Pontikake M, et al. Poliovirus vaccination in an infant with hypogammaglobulinaemia [letter]. Lancet 1998 Feb 28; 351(9103): 674PubMedCrossRef
55.
Gutierrez K, Abzug MJ. Vaccine-associated poliovirus meningitis in children with ventriculoperitoneal shunts. J Pediatr 1990 Sep; 117(3): 424–7PubMedCrossRef
56.
Kinnunen E, Farkkila M, Hovi T, et al. Incidence of Guillain-Barré syndrome during a nationwide oral poliovirus vaccine campaign. Neurology 1989; 39: 1034–6PubMedCrossRef
57.
Uhari M, Rantala H, Niemelä M. Cluster of childhood Guillain-Barré cases after an oral poliovaccine campaign. Lancet 1989 Aug 19; 2: 440–1PubMedCrossRef
58.
Rantala H, Cherry JD, Shields WD, et al. Epidemiology of Guillain-Barré syndrome in children: relationship of oral polio vaccine administration to occurrence. J Pediatr 1994; 124(2): 220–3PubMedCrossRef
59.
Kinnunen E, Junttila O, Haukka J, et al. Nationwide oral polio-virus vaccination campaign and the incidence of Guillain-Barré syndrome. Am J Epidemiol 1998; 147(1): 69–73PubMedCrossRef
60.
Harjulehto T, Hovi T, Aro T, et al. Congenital malformations and oral poliovirus vaccination during pregnancy. Lancet 1989 Apr 8; I: 771–2CrossRef
61.
Harjulehto-Mervaala T, Aro T, Hiilesmaa VK, et al. Oral polio vaccination during pregnancy: no increase in the occurrence of congenital malformations. Am J Epidemiol 1993; 138(6): 407–14PubMed
62.
Ornoy A, Ben Ishai P. Congenital anomalies after oral poliovirus vaccination during pregnancy [letter]. Lancet 1993 May 1; 341: 1162PubMedCrossRef
63.
Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1991; 14: 568–79CrossRef
64.
Begg NT, Chamberlain R, Roebuck M. Paralytic poliomyelitis in England and Wales 1970–84. Epidemiol Infect 1987; 99: 97–106PubMedCrossRef
65.
Andrus JK, Strebel PM, de Quadros CA, et al. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989–91. Bull World Health Organ 1995; 73(1): 33–40PubMed
66.
Sutter RW, Prevots R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 1994 June; 11(6): 426, 429–30, 435–8
67.
Centers for Disease Control and Prevention. Prolonged polio-virus excretion in an immunodeficient persons with vaccine-associated paralytic poliomyelitis. MMWR Morb Mortal Wkly Rep 1997; 46(28): 641–3
68.
Strebel PM, Ion-Nedelcu N, Baughman AL, et al. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine: a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med 1995 Feb 23; 332(8): 500–6PubMedCrossRef
69.
Izurieta HS, Sutter RW, Baughman AL, et al. Vaccine-associated paralytic poliomyelitis in the United States: no evidence of elevated risk after simultaneous intramuscular injections of vaccine. Pediatr Infect Dis J 1995 Oct; 14(10): 840–6PubMedCrossRef
70.
Black SB, Shinefield HR, Ray P, et al. Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy. Pediatr Infect Dis J 1993 Dec; 12(2): 981–5PubMedCrossRef
71.
Vadheim CM, Greenberg DP, Partridge S, et al. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Pediatrics 1993 Aug; 92(2): 272–9PubMed
72.
Centers for Disease Control and Prevention. Haemophilus B conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991 Jan 11; 40(RR-1): 1–7
73.
Centers for Disease Control and Prevention. Recommendations for use of Haemophilus B conjugate vaccines and a combined diphtheria, tetanus, pertussis, and haemophilus B vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1993: 42(RR-13): 1–15
74.
Leroy V, Ladner J, Nsengumuremyi F, et al. Safety of Haemophilus influenzae conjugate vaccine in children born to HIV-1 infected mothers: Kigali (Rwanda), 1992–1994. Vaccine 1996; 14(2): 177–8PubMedCrossRef
75.
Dockrell DH, Poland GA, Mitchell PS, et al. Effect of Haemophilus influenzae type b immunization on HIV viremia in HIV-seropositive adults. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 512–4PubMedCrossRef
76.
Milstien JB, Gross TP, Kuritsky JN. Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: an analysis after 1 year of marketing. Pediatrics 1987 Aug; 80(2): 270–4PubMed
77.
Black SB, Shinefield HR, Hiatt RA, et al. Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine. Pediatr Infect Dis J 1988; 7: 149–56PubMedCrossRef
78.
Harrison LH, Broome CV, Hightower AW, et al. A day care-based study of the efficacy of Haemophilus b polysaccharide vaccine. JAMA 1988; 260: 1413–8PubMedCrossRef
79.
Osterholm MT, Rambeck JH, White KE, et al. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA 1988; 260: 1423–8PubMedCrossRef
80.
Lepow ML, Samuelson JS, Gordon LK. Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide-diphtheria toxoid conjugate vaccine in adults. J Infect Dis 1984; 150: 402–6PubMedCrossRef
81.
Niu M, Davis D, Ellenberg S. Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System (VAERS). Pediatr Infect Dis J 1996 Sep; 15(9): 771–6PubMedCrossRef
82.
Niu M, Rhodes P, Salive M, et al. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 1998; 51(6): 503–10PubMedCrossRef
83.
Dobson S, Scheifele D, Bell A. Assessment of a universal, school-based hepatitis B vaccination program. JAMA 1995 Oct 18; 274(15): 1209–13PubMedCrossRef
84.
Pope J, Stevens A, Howson W, et al. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheum 1998; 25: 1687–93PubMed
85.
Bracci M, Zoppini A. Polyarthritis associated with hepatitis B vaccination. Br J Rheumatol 1997; 36(2): 300–1PubMedCrossRef
86.
McMahon BJ, Helminiak C, Wainwright RB, et al. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992 Mar; 92: 254–6PubMedCrossRef
87.
Malawista SE. Infectious arthritis. In: Wyngaarden JB, Smith LH, Bennett JC, editors. Cecil textbook of medicine. 19th ed. Philadelphia (PA): WB Saunders Co, 1992: 1520–1
88.
Gross K, Combe C, Krüger K, et al. Arthritis after hepatitis B vaccination. Scand J Rhematol 1995; 24: 50–2CrossRef
89.
Hachulla E, Houvenagel E, Mingul A, et al. Reactive arthritis after hepatitis B vaccination: case report questions cross reacting antigenic determinants between infecting agents and HLA-B27. J Rhematol 1990; 17: 1250–1
90.
Biasi D, DeSandre G, Bambara LM, et al. A new case of reactive arthritis after hepatitis B vaccination [letter]. Clin Exp Rheumatol 1993; 11: 215PubMed
91.
Vautier G, Carty JE. Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination [letter]. Br J Rheumatol 1994; 33: 991PubMedCrossRef
92.
Shaw FE, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Am J Epidemiol 1988; 127(3): 337–52PubMed
93.
Kaplanski G, Retornaz F, Durand JM, et al. Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype. J Neurol Neurosurg Psychiatry 1995; 58(6): 758–9PubMedCrossRef
94.
Tartaglino LM, Heiman-Patterson T, Friedman DP, et al. MR imaging in a case of postvaccination myelitis. Am J Neuroradiol 1995; 16: 581–2PubMed
95.
Albitar S, Bourgeon B, Genin R, et al. Bilateral retrobulbar optic neuritis with hepatitis B vaccination. Nephrol Dial Transplant 1997; 12: 2169–70PubMedCrossRef
96.
Carmeli Y, De-Medina T. Serious hepatitis B vaccine adverse reactions, are they immune-mediated? Vaccine 1993; 11: 1358–9PubMedCrossRef
97.
Grotto I, Mandel Y, Ephros M, et al. Major adverse reaction to yeast-derived hepatitis B vaccines: a review. Vaccine 1998; 16(4): 329–34PubMedCrossRef
98.
Fujinami RS, Oldstone MBA. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985 Nov 29; 230: 1043–5PubMedCrossRef
99.
Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695–705PubMedCrossRef
100.
Herroelen L, DeKeyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991 Nov 9; 338: 1174–5PubMedCrossRef
101.
Halsey NA, Duclos P, Van Damme P, et al. Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board. Pediatr Infect Dis J 1999; 18: 23–4PubMedCrossRef
102.
Brezin AP, Lautier-Frau M, Hamedani M, et al. Visual loss and eosinophilia after recombinant hepatitis B vaccine. Lancet 1993 Aug 28; 342(8870): 563–4PubMedCrossRef
103.
Maillefert JF, Farge P, Gazet-Maillefert MP, et al. Mental nerve neuropathy as a result of hepatitis B vaccination. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 June; 83: 663–4PubMedCrossRef
104.
105.
Devin F, Roques G, Disdier P, et al. Occlusion of central retinal vein after hepatitis B vaccination [letter]. Lancet 1996 Jun 8; 347: 1626PubMedCrossRef
106.
Castresana-Isla CJ, Herrera-Martinez G, Vega-Molina J. Erythema nodusum and Takayasu’s arteritis after immunization with plasma derived hepatitis B vaccine. J Rheumatol 1993; 20: 1417–8PubMed
107.
Manna R, DeSantis A, Oliviero A, et al. Leucoencephalitis after recombinant hepatitis B vaccine. J Hepatol 1996; 24(6): 764–5PubMedCrossRef
108.
Mathieu E, Fain O, Krivitzky A. Cryoglobulinemia after hepatitis B vaccination [letter]. N Engl J Med 1996 Aug; 335(5): 355PubMedCrossRef
109.
Lilic D, Ghosh SK. Liver dysfunction and DNA antibodies after hepatitis B vaccination. Lancet 1994 Nov 5; 344(8932): 1292–3PubMedCrossRef
110.
Germanaud J, Causse X, Trinh D, et al. A case of severe cytolysis after hepatitis B vaccination [letter]. Am J Med 1995 Jun; 98(6): 595PubMedCrossRef
111.
Poullin P, Gabriel B. Thrombocytopenic purpura after recombinant hepatitis B vaccine [letter]. Lancet 1994 Nov 5; 344(8932): 1293PubMedCrossRef
112.
Ronchi F, Cecchi P, Falcioni F, et al. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine. Arch Dis Child 1998; 78(3): 273–4PubMedCrossRef
113.
Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. JAMA 1997 Oct 9; 278(14): 1176–8PubMedCrossRef
114.
115.
Alleged link between hepatitis B vaccine and chronic fatigue syndrome. Canada Dis Wkly Rep 1991 Oct 5; 17–40: 215–6
116.
Redd S, Markowitz L, Katz S. Measles. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia (PA): WB Saunders, 1999: 222–66
117.
Fasano MB, Wood RA, Cooke SK, et al. Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine. J Pediatr 1992; 120: 878–81PubMedCrossRef
118.
James JM, Burks AW, Roberson PK, et al. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332: 1262–6PubMedCrossRef
119.
Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol 1993 April; 91(4): 867–72PubMedCrossRef
120.
Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol 1995; 96: 563–5PubMedCrossRef
121.
Rowlands DF, Freestone DS. Vaccination against rubella of susceptible schoolgirls in Reading. J Hygiene 1971; 69: 579–86CrossRef
122.
Slater PE, Ben-Zvi T, Fogel A, et al. Absence of an association between rubella vaccination and arthritis in underimmune postpartum women. Vaccine 1995; 13: 1529–32PubMedCrossRef
123.
Frenkel LM, Nielsen K, Garakian A, et al. A search for persistent rubella virus infection in persons with chronic symptoms after rubella and rubella immunization and in patients with juvenile rheumatoid arthritis. Clin Infect Dis 1996; 22: 287–94PubMedCrossRef
124.
Ray P, Black S, Shrinefield H. Risk of chronic arthropathy among women after rubella vaccination. JAMA 1997; 278: 551–6PubMedCrossRef
125.
Tingle AJ, Mitchell LA, Grace M, et al. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. Lancet 1997; 349: 1277–81PubMedCrossRef
126.
Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) project. Pediatr Infect Dis J 1997; 16: 500–3PubMedCrossRef
127.
Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993; 341: 979–95PubMedCrossRef
128.
Silveira CM, Salisbury DM, de Quadros CA. Measles vaccination and Guillain-Barré syndrome. Lancet 1997; 349: 14–6PubMedCrossRef
129.
Dyken PR, Cunningham SC, Ward LC. Changing character of subacute sclerosing panencephalitis in the United States. Pediatr Neurol 1989 Nov-Dec; 5(6): 339–41PubMedCrossRef
130.
American Academy of Pediatrics. Measles. In: Peter G, editor. 1997 red book report of the Committee on Infectious Diseases. Elk Grove Village (IL): American Academy of Pediatrics, 1997: 344
131.
Alderslade R, Bellman MH, Rawson NSB, et al. The national childhood encephalopathy study: a report on 1000 cases of serious neurological disorders in infants and young children from the NCES research team. In: Department of Health and Social Security. Whooping cough: reports from the Committee on the Safety of Medicines and the Joint Committee on Vaccination and Immunization. London: Her Majesty’s Stationery Office, 1981
132.
Miller D, Wadsworth J, Diamond J, et al. Measles vaccination and neurological events [letter]. Lancet 1997; 349: 729–30
133.
Weibel RE, Caserta V, Benor DE, et al. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program. Pediatrics 1998; 101: 383–7PubMedCrossRef
134.
Hughes R, Rees J, Smeeton N, et al. Vaccines and Guillain-Barré syndrome [letter]. Lancet 1996; 312: 1475–6
135.
Centers for Disease Control and Prevention. Adverse events following immunization. Surveillance Report No. 3, 1985-1986, Atlanta (GA): Department of Health and Human Services, Public Health Service, CDC 1989
136.
Wakefield AJ, Pittilo RM, Sim R, et al. Evidence of persistent measles infection in Crohn’s disease. J Med Virol 1993; 39: 345–53PubMedCrossRef
137.
Ekbom A, Daszak P, Kraaz W, et al. Crohn’s disease after inutero measles exposure. Lancet 1996; 348: 515–7PubMedCrossRef
138.
Duclos P, Ward BJ. Measles vaccines: a review of adverse events. Drug Saf 1998; 6: 435–54CrossRef
139.
Liu Y, van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia colt, and Streptococcus antigens in Crohn’s disease. Gastroenterology 1995; 108: 1396–404PubMedCrossRef
140.
Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026–9PubMedCrossRef
141.
Feeney M, Clegg A, Winwood P, et al. A case-control study of measles vaccination and inflammatory bowel disease. Lancet 1997; 350: 764–6PubMedCrossRef
142.
Haga Y, Funakoshi O, Kuroe K, et al. Absence of measles viral genomic sequence in intestinal tissues from Crohn’s disease by nested polymerase chain reaction. Gut 1996; 38: 211–5PubMedCrossRef
143.
Chadwick N, Bruce IJ, Schepelmann S, et al. Measles virus RNA is not detected in inflammatory bowel disease using hybrid capture and reverse transcription followed by the polymerase chain reaction. J Med Virol 1998; 55: 305–11PubMedCrossRef
144.
Patriarca PA, Beeler JA. Measles vaccination and inflammatory bowel disease [comment]. Lancet 1995; 345: 1062–3PubMedCrossRef
145.
Farrington P, Miller E. Measles vaccination as a risk factor for inflammatory bowel disease [letter]. Lancet 1995; 345: 1362PubMedCrossRef
146.
MacDonald TT. Measles vaccination as a risk factor for inflammatory bowel disease [letter]. Lancet 1995; 345: 1363–4PubMed
147.
Miller D, Renton A. Measles vaccination as a risk factor for inflammatory bowel disease [letter; comment]. Lancet 1995 May 27; 345(8961): 1363PubMed
148.
Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental [comment]. Lancet 1998; 351: 611–2PubMedCrossRef
149.
Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 1996; 15: 88–90PubMedCrossRef
150.
Bayer WL, Sherman FE, Michaels RH, et al. Purpura in congenital and acquired rubella. N Engl J Med 1965; 273: 1362–6PubMedCrossRef
151.
Drachtman RA, Murphy S, Ettinger LJ, et al. Exacerbation of chronic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med 1994; 148: 326–7PubMedCrossRef
152.
Vlacha V, Forma EN, Miron D, et al. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 1996; 97: 738–9PubMed
153.
Pool V, Chen R, Rhodes P. Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura [letter]. Pediatr Infect Dis J 1997; 16: 423–4PubMedCrossRef
154.
Ward BJ. Vaccine adverse events in the new millenium: is there reason for concern? Bull World Health Organ 2000; 78: 205–15PubMed
155.
Freed GL, Katz SL, Clark SJ. Safety of vaccinations: Miss America, the media, and public health. JAMA 1996; 276: 1869–72PubMedCrossRef
156.
Chen RT, Hibbs B. Vaccine safety: current and future challenges. Pediatr Ann 1998; 27: 445–64PubMed
157.
Wood D, Saarlas KN, Inkelas M, et al. Immunization registries in the United States: implicatons for the practice of a public health in a changing healthcare system. Annu Rev Public Health 1999; 20: 231–55PubMedCrossRef
158.
Khoury MJ, Risch N, Kelsey JL. Genetic epidemiology. Epidemiol Rev 1997; 19: 1–185CrossRef
Metadaten
Titel
Safety of Routine Childhood Vaccinations
An Epidemiological Review
verfasst von
Dr Robert T. Chen
Gina Mootrey
Frank DeStefano
Publikationsdatum
01.07.2000
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 4/2000
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/00128072-200002040-00004

Weitere Artikel der Ausgabe 4/2000

Pediatric Drugs 4/2000 Zur Ausgabe

Disease Management

Haemolytic Uraemic Syndrome

Adis Drug Evaluation

Lamotrigine

Disease Management

Management of Schizophrenia in Children and Adolescents

Teaching Case

Varicella Zoster Infection in HIV-Infected Children

Review Article

Role of Drug Therapy in the Treatment of Gastro-Oesophageal Reflux Disorder in Children

Neu im Fachgebiet Pädiatrie

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Reanimation bei Kindern – besser vor Ort oder während Transport?

29.05.2024 Reanimation im Kindesalter Nachrichten

Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

24.05.2024 Pränatale und perinatale Diagnostik Nachrichten

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise